Physician profile
Neil Kramer
NPI 1306808746
$37,473.39
in general payments reported to CMS, 2019-2025
38 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,043 · 2020: $277 · 2021: $17K · 2022: $6,844 · 2023: $8,166 · 2024: $2,865 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,505 · Food and Beverage: $3,480 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,505.00 |
| Food and Beverage | $3,480.33 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25,062.11 | 2019-2024 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $5,476.49 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $2,098.06 | 2019-2025 | Orencia, Sotyktu |
| Novartis Pharmaceuticals Corporation | $1,034.64 | 2019-2025 | |
| Amgen INC. | $791.26 | 2019-2025 | Evenity, Tavneos, Enbrel |
| Janssen Biotech, INC. | $519.58 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $398.75 | 2019-2025 | |
| Pfizer INC. | $384.75 | 2019-2025 | |
| Ucb, INC. | $289.26 | 2019-2025 | Bimzelx, Cimzia |
| Fresenius Kabi USA, LLC | $216.86 | 2023-2025 | Idacio |
| Horizon Therapeutics Plc | $186.02 | 2019-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.35 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| Genzyme Corporation | $103.17 | 2019-2023 | |
| Sobi, INC | $96.29 | 2019-2024 | |
| Pacira Therapeutics, INC. | $90.82 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $59.26 | 2022-2025 | Durolane |
| Radius Health, INC. | $58.77 | 2019-2024 | Tymlos |
| Genentech USA, INC. | $55.45 | 2019-2024 | Actemra |
| Organon LLC | $49.25 | 2024-2025 | Hadlima |
| Lilly USA, LLC | $46.42 | 2019-2024 | Taltz |
| Biocon Biologics INC | $38.99 | 2024 | Hulio |
| Alexion Pharmaceuticals, INC. | $35.95 | 2022-2024 | Strensiq |
| Kiniksa Pharmaceuticals International, Plc | $31.50 | 2024 | Arcalyst |
| Celgene Corporation | $29.32 | 2019 | |
| Medexus Pharma, INC. | $24.73 | 2019 | |
| Invivyd INC | $19.00 | 2025 | Pemgarda |
| Sandoz INC. | $17.92 | 2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $16.07 | 2024 | Glassia |
| Ani Pharmaceuticals, INC. | $15.88 | 2024 | Purified Cortrophin Gel |
| Octapharma USA, INC. | $15.63 | 2024 | Octagam Immune Globulin (Human) |
| Kiniksa Pharmaceuticals, LTD. | $15.57 | 2023 | Arcalyst |
| Oyster Point Pharma, INC. | $15.36 | 2023 | Tyrvaya |
| Mylan Institutional INC. | $15.00 | 2023 | Hulio, Fulphila |
| Hikma Pharmaceuticals USA | $13.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.32 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.